AstraZeneca and Bristol-Myers grabbed a win in the EU today for one of the drugs sprung from their diabetes treatment partnership. But the recommended approval comes even as questions have bubbled up about the future of that relationship.
Look up the word "likable" in an actor's guidebook, and you'd find a picture of Tom Hanks. Ask his doctor, and you'd discover he has Type 2 diabetes. Put those two together, and you have a good-natured announcement about his diagnosis this week on "Late Night with David Letterman."
A 12-year diabetes study has turned up a new biomarker that can flag a high risk for diabetes years before the disease develops. And that could eventually help physicians in the fight against the global epidemic of the disease.
Oramed, the Jerusalem-based developer of two oral diabetes products in clinical trials, landed approval for a Chinese patent of its core technology from the country's State Intellectual Property Office.
Eli Lilly and Humana have teamed up to analyze various data sets to understand disease outcomes, starting with Type 2 diabetes, the companies announced this morning.
Watchdogs worried about antipsychotic use in children now have more ammo. A new study links the drugs with Type 2 diabetes. Published in the journal JAMA Psychiatry, the study found a threefold increase in diabetes risk for kids who take antipsychotic drugs compared with those taking other psychotropic drugs.
These alliances benefit not only pharma companies, which gain access to world-class scientists and robust drug discovery programs, but also academic institutions, which increasingly are realizing that relationships with Big Pharma are more and more vital.
Chronic inflammation has long been thought to have ties to Type 2 diabetes, and now researchers at the National Institutes of Health believe they have discovered what that connection may be. The findings also point to a possible molecular target for treating the disease, which is a growing epidemic in the U.S.
Earlier this year, a study linked the GLP-1 class of drugs for Type 2 diabetes to an increased risk of pancreatic cancer. Today, the European Medicines Agency said the data just are not substantial enough to make the connection.
New research that unmasks the shape of a promising target for treating Type 2 diabetes could change the way scientists design drugs to regulate glucose in diabetics.